President Trump’s “most-favored-nation” drug pricing pilot for Medicaid is encountering hesitation from mid-sized and smaller pharmaceutical companies. While 17 large drugmakers have signed on, smaller firms argue the business model is ill-suited for their concentrated portfolios, raising questions about the initiative's long-term participation and broader market impact.
What Happened
The Trump administration’s push to lower U.S. prescription drug prices to match the lowest rates paid globally—a policy known as “most-favored-nation” (MFN) pricing—is facing practical hurdles. While the government has secured agreements with 17 of the world’s largest pharmaceutical manufacturers to lower prices for Medicaid, efforts to enlist the broader industry have slowed. The application period for the government's Medicaid pilot, known as the GENEROUS model, concluded in June after several extensions, highlighting the difficulty in achieving universal industry buy-in.
The White House has projected that these MFN agreements could yield significant savings for federal and state governments, but these figures remain the subject of debate. The program relies on voluntary participation from drugmakers, and many smaller firms are opting to remain on the sidelines, concerned about the potential impact on their profit margins and overall business strategy.
The Business Model Mismatch
The primary friction point for smaller and mid-sized pharmaceutical companies is the difference in their business models compared to larger counterparts. Large, diversified pharmaceutical companies often have extensive portfolios, allowing them to balance price concessions on specific drugs against broader revenue streams. In contrast, smaller firms frequently focus on a limited number of innovative, high-value therapies.
For these smaller players, participating in the MFN program could lead to concentrated revenue hits. Executive leadership at these firms has expressed concern that price cuts could severely impact their financial health, especially when they lack the scale to absorb lower pricing without jeopardizing research and development funding. This concentration risk makes the voluntary nature of the pilot program difficult for smaller companies to accept, as they see little upside compared to the potential loss of revenue autonomy.
Regulatory And Legal Uncertainty
Beyond the specific Medicaid pilot, the administration is exploring broader, potentially mandatory pilots for Medicare—a program where drug spending is significantly higher than in Medicaid. This has prompted strong opposition from industry organizations such as PhRMA and BIO, which have criticized the policy on legal and constitutional grounds.
Industry groups argue that these initiatives overstep regulatory authority and may face the same legal challenges that have stalled past drug pricing efforts. Pharmaceutical consultants note that many firms are adopting a “wait-and-see” approach, monitoring the rollout of the current Medicaid pilot and waiting for clarity on legal challenges before committing to any agreements. The administration’s reliance on using Centers for Medicare & Medicaid Services (CMS) powers in this manner remains largely untested, creating a layer of regulatory uncertainty that hangs over the entire sector.
What Investors Should Monitor
Investors should keep a close watch on the participation rate of state governments, which have the final say on their involvement in the Medicaid pilot. Additionally, the viability of the projected savings will depend on how many drugs are covered under these agreements and whether the administration pursues mandatory Medicare programs, which would likely face intense legal scrutiny. Monitoring management commentary from smaller pharma firms regarding their pricing strategy and potential impact from these regulatory shifts will be essential to gauge the potential risk to their future margins.